2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$520,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2164 (117th), H.R. 7506 (117th), H.R. 5801 (117th), H.R. 1176 (117th), H.R. 3 (117th), H.R. 19 (117th), H.R. 5376 (117th), S.Res. 683 (117th)

Medicare/Medicaid MMM

Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th)

Budget/Appropriations BUD

Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2599 (117th), H.R. 4356 (117th)

Medical/Disease Research/Clinical Labs MED

General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3799 (117th), S. 1260 (117th), H.R. 4521 (117th), S. 4348 (117th), H.R. 7667 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.